Graeme Fraser
Chief Tech/Sci/R&D Officer at Ogeda SA
Profile
Graeme Fraser is currently the Chief Scientific Officer at Ogeda SA. Previously, he worked as a Principal at AstraZeneca Canada, Inc. and Viron Therapeutics, Inc. He also served as the Vice President-Drug Discovery at Tranzyme Pharma, Inc. (Canada).
Dr. Fraser holds a doctorate degree from McGill University.
Graeme Fraser active positions
| Companies | Position | Start |
|---|---|---|
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Chief Tech/Sci/R&D Officer | - |
Former positions of Graeme Fraser
| Companies | Position | End |
|---|---|---|
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Corporate Officer/Principal | - |
AstraZeneca Canada, Inc.
 AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
| Tranzyme Pharma, Inc. (Canada) | Corporate Officer/Principal | - |
Training of Graeme Fraser
| McGill University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Health Technology |
| Tranzyme Pharma, Inc. (Canada) | |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
AstraZeneca Canada, Inc.
AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Graeme Fraser
